The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Robert Justin Marcus - JPMorgan Chase & Co, Research Division - Analyst
: Congrats on good quarter. Maybe to start, it's hard to escape it. GLP-1 is becoming a very big topic in med tech. And your -- it's
impacting bariatric surgery here. It doesn't seem to be impacting anything else, particularly in the pipeline. But just wondering your
thoughts overall, could GLP-1s ultimately be a positive as more people try weight loss surgery and come in the funnel? And any
other impacts good or bad that you foresee on business?
Question: Robert Justin Marcus - JPMorgan Chase & Co, Research Division - Analyst
: No, I had a financial question for Jamie, if that's okay, after.
Question: Robert Justin Marcus - JPMorgan Chase & Co, Research Division - Analyst
: Jamie, it looks like the fourth quarter gross margin is ticking down a bit, and you're talking about the increased depreciation cost
and some of these new investments here. I was wondering if you could size the amount, and I'm really looking for how to think about
into next year with depreciation, so we could get our gross margin set based on whatever expansion or contraction we're all
forecasting.
Question: Brandon Vazquez - William Blair & Company L.L.C., Research Division - Analyst
: Maybe my first one, I wanted to talk a little bit about general surgery, that's obviously been a nice growth path for you here in the
U.S. My understanding is it's a little less penetrated international. What do you think needs to happen in the international markets
to kind of get on that steep part of the adoption curve for general surgery as well? Are they kind of seeing time lines and catalysts
in the U.S?
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
OCTOBER 19, 2023 / 8:30PM, ISRG.OQ - Q3 2023 Intuitive Surgical Inc Earnings Call
Question: Brandon Vazquez - William Blair & Company L.L.C., Research Division - Analyst
: Great. And then maybe last one for me as a follow-up, I think last quarter, you guys were talking a little bit about launching, I believe
it was called Case Insights, kind of the software AI platform. Any kind of updates on that end? How are things going so far? And
maybe what's in the future for that program?
|
